可能支持识别银屑病患者中银屑病关节炎发展的临床、遗传和组学生物标志物:一项文献叙述性综述
约25%-30%的皮肤银屑病患者会发展为银屑病关节炎,但目前原因未明且诊断治疗延迟明显。本叙述性综述纳入2020年5月至2024年5月间发表的38篇文献,评估临床危险因素与新型分子生物标志物。甲受累是最强的临床危险因素之一,而分子生物标志物未能清晰稳健区分皮肤银屑病与银屑病关节炎组,可能主要归因于研究人群小和研究设计异质性。
要点
- 约25%-30%的皮肤银屑病患者会发展为银屑病关节炎。
- 甲受累是银屑病关节炎发展最强的临床危险因素之一。
- 分子生物标志物未能清晰稳健区分皮肤银屑病与银屑病关节炎组。
核心结论
- 分子生物标志物未能提供皮肤银屑病与银屑病关节炎组间清晰稳健的区分,其表现不佳可能主要归因于研究人群小和研究设计异质性。
- 甲受累是银屑病关节炎发展的最强临床危险因素之一,与既往综述结果相似。
- 大型联盟(如HIPPOCRATES)的数据和样本共享可能有助于克服小研究的局限性,并促进开发更稳健的银屑病关节炎诊断和筛查工具。
研究设计与样本
- 叙述性文献综述,纳入2020年5月至2024年5月间发表的38篇文献。
- 评估的内容包括临床危险因素和新型分子生物标志物(遗传标志物、血液和炎症标志物、脂质、代谢物和蛋白质生物标志物)。
主要发现
- 约25%-30%的皮肤银屑病患者会发展为银屑病关节炎。
- 甲受累是银屑病关节炎发展的最强临床危险因素之一。
- 分子生物标志物未能提供皮肤银屑病与银屑病关节炎组间清晰稳健的区分。
局限性
- 分子标志物表现看似不佳可能主要归因于研究人群小和研究设计异质性。
- 数据和样本共享在HIPPOCRATES等大型联盟中可能有助于克服小研究的局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
It is known that 25%-30% of individuals with cutaneous psoriasis (PsC) will develop psoriatic arthritis (PsA). To date, the reasons for the development of PsA in individuals with PsC have not been identified. Furthermore, there are considerable delays in the diagnosis and treatment of PsA, which lead to joint and bone deformation and chronic pain. It is therefore important to develop more precise diagnostic and screening tools. In this narrative review of the literature, clinical risk factors and novel molecular biomarkers (genetic markers, blood and inflammatory markers, lipid, metabolite and protein biomarkers) have been evaluated. The review included 38 publications that were reported between May 2020 and May 2024. Similar to previous reviews, nail involvement was one of the strongest clinical risk factors for the development of PsA, while molecular biomarkers did not provide a clear and robust differentiation between PsC and PsA groups. The seemingly poor performance of molecular markers may be largely attributed to small study populations and heterogeneity in study designs. Data and sample sharing in large consortia such as HIPPOCRATES (Health initiatives in Psoriasis and PsOriatic arthritis ConsoRTium European States) could help to overcome the limitations of small studies and enable the development of more robust diagnostic and screening tools for PsA.
引用
- Grohmann T, Vivekanantham A, Coates LC, et al. Clinical, genetic and omics-based biomarkers that might support the identification of the development of psoriatic arthritis in individuals with psoriasis: a narrative review of the literature. RMD Open. 2024. PMID: 39672590. doi:10.1136/rmdopen-2024-004176
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。